Nammi Therapeutics

Nammi Therapeutics | Next stage in Immuno-Oncology | Los Angeles

Nammi Therapeutics is an immunotherapy company developing first in class products for the treatment of cancer. We are developing products that focus immune ...

Nammi Therapeutics, Inc. - LinkedIn

Nammi Therapeutics, Inc. | 695 followers on LinkedIn. Nammi aims to improve cancer care by co-delivering combinations of immunotherapy to ...

Advances Clinical Development of Lead Program, QXL138AM - MMRF

Nammi Therapeutics, Inc. is an immuno-oncology company based in Los Angeles that is developing platforms and products that selectively activate ...

Nammi Therapeutics - Graduated Companies

Nammi Therapeutics, Inc. is focused on optimizing cancer immunotherapy by using nanocarriers to deliver synergistic anti-tumor and immune activating agents ...

Nammi Therapeutics, Inc. Announces First Patient Dosed with ...

Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma.

Nammi Therapeutics doses first subject in trial of QXL138AM for ...

Nammi Therapeutics has commenced the first-in-human Phase I trial of QXL138AM by dosing the first subject.

Nammi Therapeutics, Inc. Announces First Patient Dosed with ...

PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi), a clinical stage immuno-oncology company with a diverse pipeline created with the ...

Nammi Therapeutics doses first subject in trial of QXL138AM for ...

The therapy also received ODD from the US Food and Drug Administration (FDA) for multiple myeloma in the same year. "Nammi Therapeutics doses ...

Nammi Therapeutics, Inc. – CIRM

Nammi Therapeutics, Inc. ... Short Name: Nammi Therapeutics, Inc. Awards to the Institution. Program Type ...

Myeloma Investment Fund invests in Nammi Therapeutics, Inc.'s ...

Jones Day advised Myeloma Investment Fund in $1 million investment in Nammi Therapeutics, Inc.'s Series B financing.

First Patient Administrated with QXL138AM in Phase 1 Trial by ...

Nammi Therapeutics, Inc. has reported the first patient has received QXL138AM in a Phase 1 trial focused on advanced solid tumors and ...

NAMMI THERAPEUTICS, INC - Orphanet

Nammi Therapeutics, Inc. 90024 LOS ANGELES UNITED STATES Phone 1: [email protected] Institution's website More information

Nammi Therapeutics - Crunchbase Company Profile & Funding

Nammi Therapeutics is an immunotherapy company that develops nano-enabled chemo-immunotherapy for the treatment of cancer.

Nammi Therapeutics, Inc. Completes Series B Round with ...

PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi) announces a $1M investment commitment by the Myeloma Investment Fund (MIF) in a $30M Series ...

Nammi Therapeutics - Valuation, Funding & Investors - PitchBook

Information on valuation, funding, cap tables, investors, and executives for Nammi Therapeutics. Use the PitchBook Platform to explore the full profile.

Nammi Therapeutics, Inc - Orphanet

Knowledge on rare diseases and orphan drugs · Search for an institution · Nammi Therapeutics, Inc.

Nammi Therapeutics Secures Series B Funding from MMRF's ...

The designed mechanism allows QXL138AM to bind to tumor cells, where proteases on the cell surface remove the mask from the IFNa, enabling it to ...

Nammi Therapeutics Completes Series B Funding - FinSMEs

Nammi Therapeutics Completes Series B Funding ... Nammi Therapeutics, Inc., a Los Angeles, CA-based immuno-oncology company, received $1M in ...

Nammi Therapeutics begins patient dosing in phase 1 study of ...

Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma.

Nammi Therapeutics - CB Insights

Nammi Therapeutics is a biotechnology company focused on the development of immuno-oncology therapies. Use the CB Insights Platform to explore Nammi ...